Lead Product(s) : ILYX-002
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Iolyx Therapeutics Announces Phase 2 Results for ILYX-002 in Autoimmune Dry Eye Disease
Details : ILYX-002 is a topical immunomodulator, being investigated for moderate-to-severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions.
Product Name : ILYX-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2025
Lead Product(s) : ILYX-002
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable